Nikolaos A. Chatzizacharias

Nikolaos A. Chatzizacharias

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nikolaos A. Chatzizacharias has a total of 567 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    International survey on neoadjuvant treatments in anatomically resectable pancreatic adenocarcinoma (INSPIRA): a real-life snapshot

    by Chiara D'ALterio, Quirino Lai, Maria Lanzone, Roberto Valente, Matteo Fabbrici da Correggio, Immacolata Iannone, Alessandro Coppola, Salah Berkane, Tomas Koltai, Lucas McCormack, et al.

  • Temporary Mesocaval Shunt: A Surgical Strategy to Facilitate Pancreatic Cancer Resection With Complex Vascular Involvement

    by Moath Alarabiyat, Sarah Powell‐Brett, Saad Rehman, Peter Labib, Ravi Marudanayagam, Bobby Dasari, Syed Soulat Raza, David Bartlett, Keith Roberts, Robert Sutcliffe, et al.

    Background: Extensive vascular involvement remains a major challenge in the surgical management of borderline and locally advanced pancreatic ductal adenocarcinoma (PDAC). Temporary mesocaval shunting (tMCS) may facilitate resection in cases of mesenteric venous occlusion or collateralisation and improve exposure of the superior mesenteric artery; however, its use in pancreatic surgery is rarely reported. Methods: We performed a retrospective case series of patients with borderline or locally advanced PDAC who underwent curative‐intent resection with intra‐operative tMCS between 2017 and 2022. Demographics, perioperative outcomes, post‐operative complications and survival were analysed using the Kaplan–Meier method. Results: Six patients underwent pancreatectomy with tMCS (three pancreaticoduodenectomies, three total pancreatectomies). Median age was 58.5 years. All shunts used cryopreserved cadaveric iliac vein grafts. Median length of stay was 13 days. Two patients (33%) developed Clavien–Dindo grade ≥III complications, including one post‐operative death. R0 resection was achieved in two patients (33%). Median overall survival was 24.8 months (33.2 months excluding post‐operative mortality), and median disease‐free survival was 8 months. Conclusion: Selective tMCS may enable resection in PDAC with extensive vascular involvement. This complex approach should be reserved for carefully selected patients at high‐volume centres with vascular expertise.


  • Effect of dual hepatic and portal vein embolization on future liver remnant function and volume prior to major hepatectomy

    by Ananya Nayak, Anitha Muthusami, Michael Wilson, Salil Karkhanis, Homoyon Mehrzad, Khalid Hussain, Ramanivas Sundareyan, Robert Peter Sutcliffe, Ravi Marudanayagam, Keith John Roberts, et al.

    Dual hepatic and portal vein embolization, also known as dual venous embolization (DVE), is a potentially superior alternative to portal vein embolization for enhancing liver regeneration prior to major hepatectomy. This study evaluates the impact of DVE on the kinetic growth rate (KGR), volume increase (VI), functional increase (FI), and the correlation between volume and functional changes in the future liver remnant (FLR). Patients who underwent DVE with pre- and post-procedure volume and functional assessments were included. Growth rates of FLR volume and function were assessed using Tc99-mebrofenate single-photon emission computed tomography-computed tomography (Tc99-m SPECT-CT) scans. Correlation coefficients (R) were calculated to evaluate the relationship between VI and FI. Among the 37 patients included, 27 proceeded to definitive surgery. The median time between DVE and the functional scan was 33 days (interquartile range [IQR], 13-69). The median increase in FLR volume was 30% (IQR, 14-50), and FLR function increased by 75% (IQR, 25-122) (p = 0.004). Median KGR (volume) was 6% (IQR, 3%-12%), and KGR (function) was 15% (IQR, 7%-23%) (p = 0.001). Pearson's correlation coefficient between VI and FI was 0.179 (confidence interval, 0.15-0.48). Functional resectability was achieved in 35 patients. The increase in FLR function following DVE is significantly greater than the increase in volume. Earlier SPECT-CT scans may reduce delays to surgery and warrant further investigation.

  • Intention to treat outcomes following management of locally advanced pancreatic ductal adenocarcinoma with curative intent: single centre cohort study

    by Moath Alarabiyat, Saad Rehman, Peter L. Labib, Sarah Powell-Brett, Lewis Hall, Dawn Edwards, Yuk T. Ma, Shivan Sivakumar, James Good, Soulat S. Raza, et al.

  • Postoperative pancreatic fistula rates decrease over the career of pancreatic surgeons: a longitudinal cohort study

    by James M. Halle-Smith, Syed S. Raza, David C. Bartlett, Nikolaos Chatzizacharias, Bobby V.M. Dasari, Ravi Marudanayagam, Robert P. Sutcliffe, Keith J. Roberts

  • Colonization of bile with gammaproteobacteria is associated with reduced survival after surgery for pancreatic cancer in patients receiving gemcitabine-based adjuvant chemotherapy

    by Charlotte E. Terry, James M. Halle-Smith, Nabeel Merali, Ravi Marudanayagam, Nikolaos Chatzizacharias, Bobby V.M. Dasari, David C. Bartlett, Syed S. Raza, Adam E. Frampton, Robert P. Sutcliffe, et al.


  • Open Access

    Necessity and Reconstruction Methods of Splenic Vein After Resection of the Portomesenteric Junction During Resections for Pancreatic Cancer

    by Moath Alarabiyat, Nikolaos Chatzizacharias

    Pancreatic cancer involving the porto-mesenteric junction (PMJ) represents a challenge to pancreatic surgeons. Restoring mesenteric venous drainage is an essential component of vascular reconstruction after tumour resection. In contrast, management of the splenic venous drainage can involve the ligation or reconstruction of the splenic vein (SV). Evidence suggests that splenic vein ligation (SVL) is commonly associated with sinistral portal hypertension (SPH), especially if multiple venous tributaries were divided to facilitate resection. Although the association between SVL and SPH is well documented, the risk of symptomatic SPH is not widely reported, presumably due to the low incidence and poor survival of pancreatic cancer patients. Splenic vein reconstruction (SVR) has been proposed to decrease the risk of SPH but is fraught with technical complexity and increased morbidity. Moreover, SVR does not guarantee the prevention of SPH, as patency rates vary and associated hemodynamic changes are unpredictable. Patient selection and the surgical expertise available can guide SV intraoperative management, taking into consideration the risks and benefits associated with each approach. A comprehensive review of the current literature highlighting the incidence and clinical impact of SPH after the resection of pancreatic cancer involving the PMJ is presented.

  • Open Access

    Management of distal cholangiocarcinoma with arterial involvement: Systematic review and case series on the role of neoadjuvant therapy

    by Lewis A Hall, Duncan Loader, Santiago Gouveia, Marta Burak, James Halle-Smith, Peter Labib, Moath Alarabiyat, Ravi Marudanayagam, Bobby V Dasari, Keith J Roberts, et al.

    BACKGROUND The use of neoadjuvant therapy (NAT) in distal cholangiocarcinoma (dCCA) with regional arterial or extensive venous involvement, is not widely accepted and evidence is sparse. AIM To synthesise evidence on NAT for dCCA and present the experience of a high-volume tertiary-centre managing dCCA with arterial involvement. METHODS A systematic review was performed according to PRISMA guidance to identify all studies reporting outcomes of patients with dCCA who received NAT. All patients from 2017 to 2022 who were referred for NAT for dCCA at our centre were retrospectively collected from a prospectively maintained database. Baseline characteristics, NAT type, progression to surgery and oncological outcomes were collected. RESULTS Twelve studies were included. The definition of “unresectable” locally advanced dCCA was heterogenous. Four studies reported outcomes for 9 patients who received NAT for dCCA with extensive vascular involvement. R0 resection rate ranged between 0 and 100% but without survival benefit in most cases. Remaining studies considered either NAT in resectable dCCA or inclusive with extrahepatic CCA. The presented case series includes 9 patients (median age 67, IQR 56-74 years, male:female 5:4) referred for NAT for borderline resectable or locally advanced disease. Three patients progressed to surgery and 2 were resected. One patient died at 14 months with evidence of recurrence at 6 months and the other died at 51 months following recurrence 6 months post-operatively. CONCLUSION Evidence for benefit of NAT is limited. Consensus on criteria for uniform definition of resectability for dCCA is required. We propose using the established National-Comprehensive-Cancer-Network® criteria for pancreatic ductal adenocarcinoma.


  • Open Access

    Staging Computed Tomography Parameters Predict the Need for Vein Resection during Pancreaticoduodenectomy in Resectable Pancreatic Ductal Adenocarcinoma

    by Rupaly Pande, Wingyan Liu, Syed S. Raza, Michail Papamichail, Arul E. Suthananthan, David C. Bartlett, Ravi Marudanayagam, Bobby V. M. Dasari, Robert P. Sutcliffe, Keith J. Roberts, et al.

    Background: Surgery-first approach is the current standard of care for resectable pancreatic ductal adenocarcinoma (PDAC), and a proportion of these cases will require venous resection. This study aimed to identify parameters on staging computed tomography (CT) that predict the need for venous resection during pancreaticoduodenectomy (PD) for resectable PDAC. Methods: We conducted a retrospective analysis of prospectively collected data on patients who underwent PD for resectable staged PDAC (as per NCCN criteria) between 2011 and 2020. Staging CTs were independently reviewed by two specialist radiologists blinded to the clinical outcomes. Univariate and multivariate risk analyses were performed. Results: In total, 296 PDs were included. Venous resection was performed in 62 (21%) cases. There was a higher rate of resection margin positivity in the vein resection group (72.6% vs. 48.7%, p = 0.001). Tumour at the neck of the pancreas, superior mesenteric vein involvement of ≥10 mm and pancreatic duct dilatation were identified as independent predictors for venous resection. Discussion: Staging CT parameters can predict the need for venous resection during PD for resectable cases of PDAC. This may assist in surgical planning, patient selection and counselling. Future efforts should concentrate on validating these results or identifying additional predictors in a multicentre and prospective setting.


  • Open Access

    Vein Wall Invasion Is a More Reliable Predictor of Oncological Outcomes than Vein-Related Margins after Pancreaticoduodenectomy for Early Stages of Pancreatic Ductal Adenocarcinoma

    by Manish Ahuja, Rupaly Pandé, Shafiq Chugtai, Rachel M. Brown, Owen Cain, David C. Bartlett, Bobby V. M. Dasari, Ravi Marudanayagam, Keith J. Roberts, John Isaac, et al.

    Pancreaticoduodenectomy (PD) with vein resection is the only potentially curative option for patients with pancreatic ductal adenocarcinoma (PDAC) with venous involvement. The aim of our study was to assess the oncological prognostic significance of the different variables of venous involvement in patients undergoing PD for resectable and borderline-resectable with venous-only involvement (BR-V) PDAC. We performed a retrospective analysis of prospectively acquired data over a 10-year period. Of the 372 patients included, 105 (28%) required vein resection and vein wall involvement was identified in 37% of those. A multivariable analysis failed to identify the vein-related resection margins as independent predictors for OS, DFS or LR. Vein wall tumour involvement was an independent predictor of OS (risk x1.7–2) and DFS (risk x1.9–2.2) in all models, while it replaced overall surgical margin positivity as the only parameter independently predicting LR during an analysis of separate resection margins (risk x2.4). Vein wall tumour invasion may be a more reliable predictor of oncological outcomes compared to traditionally reported parameters. Future studies should focus on possible pre-operative investigations that could identify these cases and management pathways that could yield a survival benefit, such as the use of neoadjuvant treatments.